Mobile

A prospective phase I and consecutive phase II, twoarm, randomized multi-center trial of temsirolimus in combination with pioglitazone, etoricoxib and metronomic low-dose trofosfamide versus dacarb...

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-002611-29

A prospective phase I and consecutive phase II, twoarm, randomized multi-center trial of temsirolimus in combination with pioglitazone, etoricoxib and metronomic low-dose trofosfamide versus dacarbazine (DTIC) in patients with advanced melanoma

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Phase I: To determine the dose of temsirolimus to be used in phase II part of the study Phase II: To determine overall survival

Critère d'inclusion

  • metastatic melanoma or metastatic uveal carcinoma

Liens